Selective variegated methylation of the p15 CpG island in acute myeloid leukemia

Jonathan E. Dodge, Alan F. List, Bernard W Futscher

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Both p15 and p16 are tumor suppressor genes that have 5' CpG islands; aberrant cytosine methylation of these islands has been associated with silencing of their expression. Deoxycytidine kinase (dCK) converts prodrugs to their cytotoxic form, has a 5' CpG island and is a candidate gene for inactivation by hypermethylation. In our study, we used sodium bisulfite sequencing to generate high resolution maps of 5-methylcytosine in the CpG islands associated with p15, p16 and dCK in normal human bone marrow (BM), peripheral blood lymphocytes (PBL) and cytosine arabinoside (ara-C)-resistant acute myeloid leukemia (AML) patients, and established human hematopoietic tumor cell lines. In normal cells the p15, p16 and dCK CpG islands were largely unmethylated. The p16 and dCK CpG islands were also unmethylated in the 8 AML specimens. In contrast, the p15 CpG island was aberrantly methylated in 6 of the 8 AML specimens. Furthermore, bisulfite sequencing revealed that the p15 CpG island is heterogeneously methylated in AML, with large intra-individual and inter-individual variability.

Original languageEnglish (US)
Pages (from-to)561-567
Number of pages7
JournalInternational Journal of Cancer
Volume78
Issue number5
DOIs
StatePublished - 1998

Fingerprint

CpG Islands
Acute Myeloid Leukemia
Methylation
Deoxycytidine Kinase
Cytarabine
5-Methylcytosine
Cytosine
Prodrugs
Gene Silencing
Tumor Cell Line
Tumor Suppressor Genes
Islands
Bone Marrow
Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Selective variegated methylation of the p15 CpG island in acute myeloid leukemia. / Dodge, Jonathan E.; List, Alan F.; Futscher, Bernard W.

In: International Journal of Cancer, Vol. 78, No. 5, 1998, p. 561-567.

Research output: Contribution to journalArticle

@article{8facf45a653a48d8aaecbe299996aab3,
title = "Selective variegated methylation of the p15 CpG island in acute myeloid leukemia",
abstract = "Both p15 and p16 are tumor suppressor genes that have 5' CpG islands; aberrant cytosine methylation of these islands has been associated with silencing of their expression. Deoxycytidine kinase (dCK) converts prodrugs to their cytotoxic form, has a 5' CpG island and is a candidate gene for inactivation by hypermethylation. In our study, we used sodium bisulfite sequencing to generate high resolution maps of 5-methylcytosine in the CpG islands associated with p15, p16 and dCK in normal human bone marrow (BM), peripheral blood lymphocytes (PBL) and cytosine arabinoside (ara-C)-resistant acute myeloid leukemia (AML) patients, and established human hematopoietic tumor cell lines. In normal cells the p15, p16 and dCK CpG islands were largely unmethylated. The p16 and dCK CpG islands were also unmethylated in the 8 AML specimens. In contrast, the p15 CpG island was aberrantly methylated in 6 of the 8 AML specimens. Furthermore, bisulfite sequencing revealed that the p15 CpG island is heterogeneously methylated in AML, with large intra-individual and inter-individual variability.",
author = "Dodge, {Jonathan E.} and List, {Alan F.} and Futscher, {Bernard W}",
year = "1998",
doi = "10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R",
language = "English (US)",
volume = "78",
pages = "561--567",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Selective variegated methylation of the p15 CpG island in acute myeloid leukemia

AU - Dodge, Jonathan E.

AU - List, Alan F.

AU - Futscher, Bernard W

PY - 1998

Y1 - 1998

N2 - Both p15 and p16 are tumor suppressor genes that have 5' CpG islands; aberrant cytosine methylation of these islands has been associated with silencing of their expression. Deoxycytidine kinase (dCK) converts prodrugs to their cytotoxic form, has a 5' CpG island and is a candidate gene for inactivation by hypermethylation. In our study, we used sodium bisulfite sequencing to generate high resolution maps of 5-methylcytosine in the CpG islands associated with p15, p16 and dCK in normal human bone marrow (BM), peripheral blood lymphocytes (PBL) and cytosine arabinoside (ara-C)-resistant acute myeloid leukemia (AML) patients, and established human hematopoietic tumor cell lines. In normal cells the p15, p16 and dCK CpG islands were largely unmethylated. The p16 and dCK CpG islands were also unmethylated in the 8 AML specimens. In contrast, the p15 CpG island was aberrantly methylated in 6 of the 8 AML specimens. Furthermore, bisulfite sequencing revealed that the p15 CpG island is heterogeneously methylated in AML, with large intra-individual and inter-individual variability.

AB - Both p15 and p16 are tumor suppressor genes that have 5' CpG islands; aberrant cytosine methylation of these islands has been associated with silencing of their expression. Deoxycytidine kinase (dCK) converts prodrugs to their cytotoxic form, has a 5' CpG island and is a candidate gene for inactivation by hypermethylation. In our study, we used sodium bisulfite sequencing to generate high resolution maps of 5-methylcytosine in the CpG islands associated with p15, p16 and dCK in normal human bone marrow (BM), peripheral blood lymphocytes (PBL) and cytosine arabinoside (ara-C)-resistant acute myeloid leukemia (AML) patients, and established human hematopoietic tumor cell lines. In normal cells the p15, p16 and dCK CpG islands were largely unmethylated. The p16 and dCK CpG islands were also unmethylated in the 8 AML specimens. In contrast, the p15 CpG island was aberrantly methylated in 6 of the 8 AML specimens. Furthermore, bisulfite sequencing revealed that the p15 CpG island is heterogeneously methylated in AML, with large intra-individual and inter-individual variability.

UR - http://www.scopus.com/inward/record.url?scp=0031735065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031735065&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R

DO - 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R

M3 - Article

VL - 78

SP - 561

EP - 567

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -